Similar articles

• Rheumatoid arthritis in the Kingdom of Saudi Arabia.

  Merashli M, Jawad AS. Merashli M, et al. Saudi Med J. 2015 May;36(5):638. doi: 10.15537/smj.2015.5.11639. Saudi Med J. 2015. PMID: 25935189 Free PMC article. No abstract available.
• NICE guidance on rheumatoid arthritis: implications and challenges for rheumatologists.

  Walker D, Hall S. Walker D, et al. Rheumatology (Oxford). 2010 Apr;49(4):619-20. doi: 10.1093/rheumatology/kep415. Epub 2009 Dec 23. Rheumatology (Oxford). 2010. PMID: 20032225 No abstract available.
• Reply: To PMID 22473917.

  Singh JA, Saag KG, Furst D. Singh JA, et al. Arthritis Care Res (Hoboken). 2013 May;65(5):832-3. doi: 10.1002/acr.21872. Arthritis Care Res (Hoboken). 2013. PMID: 23097242 No abstract available.
• Therapy: The NICE position on indications for biologics and biosimilars.

  Scheinberg M, Gomez-Reino JJ. Scheinberg M, et al. Nat Rev Rheumatol. 2016 May;12(5):255-6. doi: 10.1038/nrrheum.2016.56. Epub 2016 Apr 15. Nat Rev Rheumatol. 2016. PMID: 27080695 Review. No abstract available.
• [Guidelines for usage of biological agents for treatment of rheumatoid arthritis].

  Takeuchi T. Takeuchi T. Nihon Rinsho. 2005 Jan;63 Suppl 1:444-7. Nihon Rinsho. 2005. PMID: 15799396 Review. Japanese. No abstract available.